Asbestos-related Diseases最新文献

Suppressed Immune System Caused by Exposure to Asbestos and Malignant Mesothelioma 接触石棉和恶性间皮瘤引起的免疫系统抑制

Asbestos-related Diseases Pub Date : 2020-01-08 DOI: 10.5772/intechopen.90763

Y. Nishimura, N. Kumagai-takei, Suni Lee, K. Yoshitome, T. Otsuki

{"title":"Suppressed Immune System Caused by Exposure to Asbestos and Malignant Mesothelioma","authors":"Y. Nishimura, N. Kumagai-takei, Suni Lee, K. Yoshitome, T. Otsuki","doi":"10.5772/intechopen.90763","DOIUrl":"https://doi.org/10.5772/intechopen.90763","url":null,"abstract":"Mesothelioma is the most serious of the asbestos-related diseases. It is caused by exposure to relatively low doses of asbestos and takes a long period to develop, which suggests the enactment of gradual adverse effects other than cellular toxicity. The immune system, which can play a role in tumor prevention, is a presumable target of asbestos by accumulation in lymph nodes and then slowly affecting functions of immune cells. Here, we describe key findings obtained from our studies concerning the immune-suppressive effects of asbestos and functional alteration in immune cells of patients with mesothelioma as well as plaque-positive subjects. Asbestos exposure of cell cultures resulted in decreased natural and acquired cytotoxicity exerted by NK cells and CTLs and the ability of Th1 cells to activate and support antitumor immunity. In contrast, asbestos exposure augmented Treg cell function and generation of fibrogenic/suppressive macrophages. Mesothelioma patients also showed similar characteristics in certain alterations caused by asbestos exposure. Additionally, our recent study established immunological screening devices for mesothelioma and asbestos exposure on the basis of comprehensive analysis of peripheral blood. Those findings underscore the importance of the immunological effects of asbestos and should assist further understanding of the mechanism and early detection of mesothelioma.","PeriodicalId":136471,"journal":{"name":"Asbestos-related Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115843827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Asbestos-Related Diseases and Blood Biomarkers 石棉相关疾病和血液生物标志物

Asbestos-related Diseases Pub Date : 2019-10-09 DOI: 10.5772/intechopen.89438

A. Franko, V. Dolžan, K. Goričar, M. Fikfak

引用次数: 0

Asbestos Exposure Results in Asbestosis and Usual Interstitial Pneumonia Similar to Other Causes of Pneumoconiosis 石棉暴露导致石棉沉滞和常见的间质性肺炎，类似于其他原因的尘肺病

Asbestos-related Diseases Pub Date : 2019-09-13 DOI: 10.5772/intechopen.89247

Y. Kawabata

引用次数: 1

Immunocheckpoint Blockade in Malignant Pleural Mesothelioma 恶性胸膜间皮瘤的免疫检查点阻断

Asbestos-related Diseases Pub Date : 2019-09-05 DOI: 10.5772/intechopen.89116

N. Fujimoto

{"title":"Immunocheckpoint Blockade in Malignant Pleural Mesothelioma","authors":"N. Fujimoto","doi":"10.5772/intechopen.89116","DOIUrl":"https://doi.org/10.5772/intechopen.89116","url":null,"abstract":"Targeting immunocheckpoint with immunomodulatory monoclonal antibodies has proven to be an effective antitumor strategy across a variety of cancers. The immunosuppressive tumor microenvironment in malignant pleural mesothelioma (MPM) has suggested that MPM might benefit from this kind of immunotherapy. In recent years, immunocheckpoint inhibitors (ICIs) have shown encouraging results for patients with MPM. Antibodies against programmed death 1 (PD-1) and PD-ligand 1 (PD-L1) have demonstrated favorable response, progression-free survival, and overall survival. The toxicity profiles were similar to those observed with ICIs in other malignancies, like melanoma and non-small cell lung cancer, and they appeared to be manageable. Nivolumab, an anti-PD-1 antibody, was approved in Japan for advanced or metastatic MPM patients resistant or intolerant to other chemotherapies. Important future issues include developing a combination therapy, where ICIs are combined with other agents (including other ICIs), and developing biomarkers for determining which patients might respond well and which might experience unacceptable toxicities. first-line therapy in unresectable MPM. The primary endpoint of the study, OS, will be reported in the near future.","PeriodicalId":136471,"journal":{"name":"Asbestos-related Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132362677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Potential Roles of Matrix Metalloproteinases in Malignant Mesothelioma 基质金属蛋白酶在恶性间皮瘤中的潜在作用

Asbestos-related Diseases Pub Date : 2019-08-19 DOI: 10.5772/INTECHOPEN.88783

Shibo Ying, Yanbin Wang, Lyuyang Lyu

引用次数: 1